Preclinical development of the TLR4 antagonist FP12 as a drug lead targeting the HMGB1/MD-2/TLR4 axis in lethal influenza infection.

Innate Immun · 2025 · PMC11877469 · PMID 40033742

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Figure 6(a) shows that the combined results of two separate experiments (n = 10 mice/treatment) recapitulate the data seen in Figure 5(b) , indicating that the protection afforded by FP12 is highly significant when administered by either the i.v. or i.p. routes.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.